| ![](/images/empty_line.GIF) |
| |
| |
| |
| |
![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) |
![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) |
PR:P51587 | breast cancer type 2 susceptibility protein (human) | | | ![](/images/empty_line.GIF) | | |
![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) |
![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) |
PR:000064511 | breast cancer type 2 susceptibility protein sequence variant K3032* (human) | | | ![](/images/empty_line.GIF) | | |
| |
| |
![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) |
![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) |
PR:P51587 | breast cancer type 2 susceptibility protein (human) | | | ![](/images/empty_line.GIF) | | |
![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) |
![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) |
PR:000064511 | breast cancer type 2 susceptibility protein sequence variant K3032* (human) | | | ![](/images/empty_line.GIF) | | |